Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
12 studies found for:    rFVIIIFc
Show Display Options
Rank Status Study
1 Not yet recruiting A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
2 Not yet recruiting Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
Condition: Hemophilia A
Intervention: Biological: Recombinant coagulation factor (rFVIIIFc)
3 Active, not recruiting Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
Condition: Severe Hemophilia A
Intervention: Biological: rFVIIIFc
4 Completed Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: rFVIIIFc
5 Enrolling by invitation Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
Condition: Hemophilia A
Intervention: Drug: rFVIIIFc
6 Completed
Has Results
Pharmacokinetics of rFVIIIFc at Two Vial Strengths
Condition: Severe Hemophilia A
Intervention: Biological: rFVIIIFc
7 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
8 Completed
Has Results
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
Condition: Severe Hemophilia A
Interventions: Drug: Factor VIII (rFVIIIFc);   Drug: Advate®
9 Completed
Has Results
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
Condition: Hemophilia A
Interventions: Drug: BIIB031 (rFVIIIFc);   Drug: FVIII (PK subgroup only)
10 Terminated Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
Conditions: Hemophilia A;   Hemophilia B
Interventions: Biological: rFVIIIFc;   Biological: rFIXFc;   Drug: non-Fc FVIII replacement products;   Drug: non-Fc FIX replacement products
11 Recruiting Factor Product Utilization and Health Outcomes in Patients With Hemophilia
Conditions: Hemophilia A, Congenital;   Hemophilia B, Congenital
Intervention:
12 Recruiting A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Conditions: Haemophilia A;   Haemophilia B
Interventions: Drug: ELOCTA;   Drug: ALPROLIX

Study has passed its completion date and status has not been verified in more than two years.